<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35089317</PMID>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>18</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">2168-6114</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>182</Volume>
            <Issue>4</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Apr</Month>
              <Day>01</Day>
            </PubDate>
          </JournalIssue>
          <Title>JAMA internal medicine</Title>
          <ISOAbbreviation>JAMA Intern Med</ISOAbbreviation>
        </Journal>
        <ArticleTitle>APOL1 Risk Variants, Acute Kidney Injury, and Death in Participants With African Ancestry Hospitalized With COVID-19 From the Million Veteran Program.</ArticleTitle>
        <Pagination>
          <StartPage>386</StartPage>
          <EndPage>395</EndPage>
          <MedlinePgn>386-395</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1001/jamainternmed.2021.8538</ELocationID>
        <Abstract>
          <AbstractText Label="IMPORTANCE">Coronavirus disease 2019 (COVID-19) confers significant risk of acute kidney injury (AKI). Patients with COVID-19 with AKI have high mortality rates.</AbstractText>
          <AbstractText Label="OBJECTIVE">Individuals with African ancestry with 2 copies of apolipoprotein L1 (APOL1) variants G1 or G2 (high-risk group) have significantly increased rates of kidney disease. We tested the hypothesis that the APOL1 high-risk group is associated with a higher-risk of COVID-19-associated AKI and death.</AbstractText>
          <AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS">This retrospective cohort study included 990 participants with African ancestry enrolled in the Million Veteran Program who were hospitalized with COVID-19 between March 2020 and January 2021 with available genetic information.</AbstractText>
          <AbstractText Label="EXPOSURES">The primary exposure was having 2 APOL1 risk variants (RV) (APOL1 high-risk group), compared with having 1 or 0 risk variants (APOL1 low-risk group).</AbstractText>
          <AbstractText Label="MAIN OUTCOMES AND MEASURES">The primary outcome was AKI. The secondary outcomes were stages of AKI severity and death. Multivariable logistic regression analyses adjusted for preexisting comorbidities, medications, and inpatient AKI risk factors; 10 principal components of ancestry were performed to study these associations. We performed a subgroup analysis in individuals with normal kidney function prior to hospitalization (estimated glomerular filtration rate ≥60 mL/min/1.73 m2).</AbstractText>
          <AbstractText Label="RESULTS">Of the 990 participants with African ancestry, 905 (91.4%) were male with a median (IQR) age of 68 (60-73) years. Overall, 392 (39.6%) patients developed AKI, 141 (14%) developed stages 2 or 3 AKI, 28 (3%) required dialysis, and 122 (12.3%) died. One hundred twenty-five (12.6%) of the participants were in the APOL1 high-risk group. Patients categorized as APOL1 high-risk group had significantly higher odds of AKI (adjusted odds ratio [OR], 1.95; 95% CI, 1.27-3.02; P = .002), higher AKI severity stages (OR, 2.03; 95% CI, 1.37-2.99; P &lt; .001), and death (OR, 2.15; 95% CI, 1.22-3.72; P = .007). The association with AKI persisted in the subgroup with normal kidney function (OR, 1.93; 95% CI, 1.15-3.26; P = .01). Data analysis was conducted between February 2021 and April 2021.</AbstractText>
          <AbstractText Label="CONCLUSIONS AND RELEVANCE">In this cohort study of veterans with African ancestry hospitalized with COVID-19 infection, APOL1 kidney risk variants were associated with higher odds of AKI, AKI severity, and death, even among individuals with prior normal kidney function.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Hung</LastName>
            <ForeName>Adriana M</ForeName>
            <Initials>AM</Initials>
            <AffiliationInfo>
              <Affiliation>Tennessee Valley Healthcare System, Nashville Campus, Nashville.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Division of Nephrology &amp; Hypertension, Vanderbilt University Medical Center, Nashville, Tennessee.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Shah</LastName>
            <ForeName>Shailja C</ForeName>
            <Initials>SC</Initials>
            <AffiliationInfo>
              <Affiliation>GI Section, VA San Diego Healthcare System, San Diego, California.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Division of Gastroenterology, University of California, San Diego, San Diego.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bick</LastName>
            <ForeName>Alexander G</ForeName>
            <Initials>AG</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Genetic Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yu</LastName>
            <ForeName>Zhihong</ForeName>
            <Initials>Z</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chen</LastName>
            <ForeName>Hua-Chang</ForeName>
            <Initials>HC</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hunt</LastName>
            <ForeName>Christine M</ForeName>
            <Initials>CM</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Gastroenterology, Duke University Medical Center, Durham, North Carolina.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>VA Cooperative Studies Program Epidemiology Center, Durham VA Health Care System, Durham, North Carolina.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wendt</LastName>
            <ForeName>Frank</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Psychiatry, Yale University School of Medicine, West Haven, Connecticut.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>VA CT Healthcare Center, West Haven, Connecticut.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wilson</LastName>
            <ForeName>Otis</ForeName>
            <Initials>O</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Nephrology &amp; Hypertension, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Greevy</LastName>
            <ForeName>Robert A</ForeName>
            <Initials>RA</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chung</LastName>
            <ForeName>Cecilia P</ForeName>
            <Initials>CP</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Rheumatology and Division of Clinical Pharmacology, Vanderbilt University Medical Center, Rheumatology Section, Veterans Affairs, Nashville, Tennessee.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Suzuki</LastName>
            <ForeName>Ayako</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Gastroenterology, Duke University Medical Center, Durham, North Carolina.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>VA Cooperative Studies Program Epidemiology Center, Durham VA Health Care System, Durham, North Carolina.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ho</LastName>
            <ForeName>Yuk-Lam</ForeName>
            <Initials>YL</Initials>
            <AffiliationInfo>
              <Affiliation>Massachusetts Veterans Epidemiology Research and Information Center, VA Boston Healthcare System, Boston.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Akwo</LastName>
            <ForeName>Elvis</ForeName>
            <Initials>E</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Nephrology &amp; Hypertension, Vanderbilt University Medical Center, Nashville, Tennessee.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Polimanti</LastName>
            <ForeName>Renato</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Psychiatry, Yale University School of Medicine, West Haven, Connecticut.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>VA CT Healthcare Center, West Haven, Connecticut.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhou</LastName>
            <ForeName>Jin</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Epidemiology and Biostatistics, University of Arizona, Phoenix.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Phoenix VA Health Care System, Phoenix, Arizona.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Reaven</LastName>
            <ForeName>Peter</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Phoenix VA Health Care System, Phoenix, Arizona.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Division of Endocrinology, Department of Medicine, University of Arizona, Phoenix.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tsao</LastName>
            <ForeName>Philip S</ForeName>
            <Initials>PS</Initials>
            <AffiliationInfo>
              <Affiliation>Epidemiology Research and Information Center (ERIC), VA Palo Alto Health Care System, Palo Alto, California.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Medicine, Stanford University School of Medicine, Palo Alto, California.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gaziano</LastName>
            <ForeName>J Michael</ForeName>
            <Initials>JM</Initials>
            <AffiliationInfo>
              <Affiliation>Massachusetts Veterans Epidemiology Research and Information Center, VA Boston Healthcare System, Boston.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Division of Aging, Brigham &amp; Women's Hospital, Boston, Massachusetts.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Huffman</LastName>
            <ForeName>Jennifer E</ForeName>
            <Initials>JE</Initials>
            <AffiliationInfo>
              <Affiliation>Center for Population Genomics, Massachusetts Veterans Epidemiology Research &amp; Information Center (MAVERIC), VA Boston Healthcare System, Boston, Massachusetts.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Joseph</LastName>
            <ForeName>Jacob</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Cardiology Section, Veterans Affairs Boston, Boston, Massachusetts.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Division of Cardiovascular Medicine, Brigham &amp; Women's Hospital, Boston, Massachusetts.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Luoh</LastName>
            <ForeName>Shiuh-Wen</ForeName>
            <Initials>SW</Initials>
            <AffiliationInfo>
              <Affiliation>VA Portland Health Care System, Portland, Oregon.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Knight Cancer Institute, Oregon Health &amp; Science University, Portland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Iyengar</LastName>
            <ForeName>Sudha</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Population and Quantitative Health Sciences, Case Western Reserve University and Louis Stoke, Cleveland VA, Cleveland, Ohio.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Louis Stokes Cleveland VA Medical Center, Cleveland, Ohio.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chang</LastName>
            <ForeName>Kyong-Mi</ForeName>
            <Initials>KM</Initials>
            <AffiliationInfo>
              <Affiliation>The Corporal Michael J. Crescenz VA Medical Center, Philadelphia, Pennsylvania.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Casas</LastName>
            <ForeName>Juan P</ForeName>
            <Initials>JP</Initials>
            <AffiliationInfo>
              <Affiliation>Massachusetts Veterans Epidemiology Research and Information Center, VA Boston Healthcare System, Boston.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Medicine, Brigham &amp; Women's Hospital, Boston, Massachusetts.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Matheny</LastName>
            <ForeName>Michael E</ForeName>
            <Initials>ME</Initials>
            <AffiliationInfo>
              <Affiliation>Departments of Biomedical Informatics, Biostatistics, and Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>GREEC, TVHS VA, Nashville, Tennessee.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>O'Donnell</LastName>
            <ForeName>Christopher J</ForeName>
            <Initials>CJ</Initials>
            <AffiliationInfo>
              <Affiliation>Cardiology, VA Boston Healthcare System, Boston, Massachusetts.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Novartis.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cho</LastName>
            <ForeName>Kelly</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Massachusetts Veterans Epidemiology Research and Information Center, VA Boston Healthcare System, Boston.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Medicine, Brigham &amp; Women's Hospital, Boston, Massachusetts.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tao</LastName>
            <ForeName>Ran</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Susztak</LastName>
            <ForeName>Katalin</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Renal, Electrolyte, and Hypertension Division, Department of Medicine, University of Pennsylvania, Perelman School of Medicine, Philadelphia, Pennsylvania.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Robinson-Cohen</LastName>
            <ForeName>Cassianne</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Nephrology &amp; Hypertension, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tuteja</LastName>
            <ForeName>Sony</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>The Corporal Michael J. Crescenz VA Medical Center, Philadelphia, Pennsylvania.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Siew</LastName>
            <ForeName>Edward D</ForeName>
            <Initials>ED</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Nephrology &amp; Hypertension, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Tennessee Valley Healthcare System, Nashville VA Medical Center, Nashville, Tennessee.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <CollectiveName>VA Million Veteran Program COVID-19 Science Initiative</CollectiveName>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>I01 CX001897</GrantID>
            <Acronym>CX</Acronym>
            <Agency>CSRD VA</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>IK2 CX002027</GrantID>
            <Acronym>CX</Acronym>
            <Agency>CSRD VA</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 HG006139</GrantID>
            <Acronym>HG</Acronym>
            <Agency>NHGRI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>JAMA Intern Med</MedlineTA>
        <NlmUniqueID>101589534</NlmUniqueID>
        <ISSNLinking>2168-6106</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C108666">APOL1 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000075944">Apolipoprotein L1</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D058186" MajorTopicYN="Y">Acute Kidney Injury</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001741" MajorTopicYN="N">African Americans</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000075944" MajorTopicYN="N">Apolipoprotein L1</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006760" MajorTopicYN="N">Hospitalization</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014728" MajorTopicYN="Y">Veterans</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <CoiStatement><b>Conflict of Interest Disclosures:</b> Dr Hung reports grants from Veterans Health CSR&amp;D Merit Grant CX001897 and grants from Veterans Health MVP035 MVP COVID-19 Science Program during the conduct of the study; grants from Vertex Pharmaceutical outside the submitted work. Dr Bick reports personal fees from TenSixteen Bio outside the submitted work. Dr Hunt reports other from Akebia Therapeutics, Inc. Safety adjudication in COVID-19 clinical trial during the conduct of the study. Dr Wendt reports grants from NIMH outside the submitted work. Dr Akwo reports grants from American Heart Association Postdoc Award #20POST35210952/Akwo/2020 during the conduct of the study. Christopher J O'Donnell: Dr O'Donnell reports income from Novartis Institute for Biomedical Research as a salaried employee outside the submitted work. Dr Susztak reports grants from GSK, Regeneron, Bayer, BiPI, Novo Nordisk, Maze, Novartis, Gilead and other from AZ, Pfizer, Bayer, GSK Consulting outside the submitted work. Dr Siew reports grants from Veterans Health Services Research and Development Grant SDR 18-194 Million Veteran Program Gamma Program during the conduct of the study; personal fees from Akebia Therapeutics, Inc. Consultant on and personal fees from Da Vita, Inc. Honorarium for an invited educational talk on AKI epidemiology at the Da Vita Annual Physician Leadership Conference outside the submitted work; and Serves on the editorial board for the <i>Clinical Journal of the American Society of Nephrology</i>; and has received royalties as an author for UptoDate.</CoiStatement>
      <InvestigatorList>
        <Investigator ValidYN="Y">
          <LastName>Hung</LastName>
          <ForeName>Adriana</ForeName>
          <Initials>A</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Wallbom</LastName>
          <ForeName>Agnes</ForeName>
          <Initials>A</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Palacio</LastName>
          <ForeName>Ana</ForeName>
          <Initials>A</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Robey</LastName>
          <ForeName>Brooks</ForeName>
          <Initials>B</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Jhala</LastName>
          <ForeName>Darshana</ForeName>
          <Initials>D</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Fujii</LastName>
          <ForeName>Daryl</ForeName>
          <Initials>D</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Cohen</LastName>
          <ForeName>David</ForeName>
          <Initials>D</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Boyko</LastName>
          <ForeName>Edward</ForeName>
          <Initials>E</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Jacono</LastName>
          <ForeName>Frank</ForeName>
          <Initials>F</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Villareal</LastName>
          <ForeName>Gerardo</ForeName>
          <Initials>G</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Garcon</LastName>
          <ForeName>Helene</ForeName>
          <Initials>H</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Gaziano</LastName>
          <ForeName>J Michael</ForeName>
          <Initials>JM</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Lichy</LastName>
          <ForeName>Jack</ForeName>
          <Initials>J</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Norton</LastName>
          <ForeName>James</ForeName>
          <Initials>J</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Beckham</LastName>
          <ForeName>Jean</ForeName>
          <Initials>J</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Whittle</LastName>
          <ForeName>Jeffrey</ForeName>
          <Initials>J</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Huffman</LastName>
          <ForeName>Jennifer</ForeName>
          <Initials>J</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Moser</LastName>
          <ForeName>Jennifer</ForeName>
          <Initials>J</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Greco</LastName>
          <ForeName>Jennifer</ForeName>
          <Initials>J</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Walsh</LastName>
          <ForeName>Jessica</ForeName>
          <Initials>J</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Harley</LastName>
          <ForeName>John</ForeName>
          <Initials>J</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Wells</LastName>
          <ForeName>John</ForeName>
          <Initials>J</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Klein</LastName>
          <ForeName>Jon</ForeName>
          <Initials>J</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Moorman</LastName>
          <ForeName>Jonathan</ForeName>
          <Initials>J</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Constans</LastName>
          <ForeName>Joseph</ForeName>
          <Initials>J</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Fayad</LastName>
          <ForeName>Joseph</ForeName>
          <Initials>J</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Casas</LastName>
          <ForeName>Juan P</ForeName>
          <Initials>JP</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Xu</LastName>
          <ForeName>Junzhe</ForeName>
          <Initials>J</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Liao</LastName>
          <ForeName>Katherine</ForeName>
          <Initials>K</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Alexander</LastName>
          <ForeName>Kathrina</ForeName>
          <Initials>K</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Cho</LastName>
          <ForeName>Kelly</ForeName>
          <Initials>K</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Hammer</LastName>
          <ForeName>Kimberly</ForeName>
          <Initials>K</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Oursler</LastName>
          <ForeName>Kris</ForeName>
          <Initials>K</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Mattocks</LastName>
          <ForeName>Kristin</ForeName>
          <Initials>K</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Chang</LastName>
          <ForeName>Kyong-Mi</ForeName>
          <Initials>KM</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Dellitalia</LastName>
          <ForeName>Louis</ForeName>
          <Initials>L</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Hamner</LastName>
          <ForeName>Mark</ForeName>
          <Initials>M</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Whooley</LastName>
          <ForeName>Mary</ForeName>
          <Initials>M</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Murdoch</LastName>
          <ForeName>Maureen</ForeName>
          <Initials>M</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Gaddy</LastName>
          <ForeName>Melinda</ForeName>
          <Initials>M</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Godschalk</LastName>
          <ForeName>Michael</ForeName>
          <Initials>M</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Rauchman</LastName>
          <ForeName>Michael</ForeName>
          <Initials>M</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Huq</LastName>
          <ForeName>Mostaqul</ForeName>
          <Initials>M</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Tandon</LastName>
          <ForeName>Neeraj</ForeName>
          <Initials>N</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Kosik</LastName>
          <ForeName>Nicole</ForeName>
          <Initials>N</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Ratcliffe</LastName>
          <ForeName>Nora</ForeName>
          <Initials>N</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Okusaga</LastName>
          <ForeName>Olaoluwa</ForeName>
          <Initials>O</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Roussos</LastName>
          <ForeName>Panagiotis</ForeName>
          <Initials>P</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Strollo</LastName>
          <ForeName>Patrick</ForeName>
          <Initials>P</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Meyer</LastName>
          <ForeName>Paul</ForeName>
          <Initials>P</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Sriram</LastName>
          <ForeName>Peruvemba</ForeName>
          <Initials>P</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Wilson</LastName>
          <ForeName>Peter</ForeName>
          <Initials>P</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Liang</LastName>
          <ForeName>Peter</ForeName>
          <Initials>P</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Tsao</LastName>
          <ForeName>Philip S</ForeName>
          <Initials>PS</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Balasubramanian</LastName>
          <ForeName>Prakash</ForeName>
          <Initials>P</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Ramoni</LastName>
          <ForeName>Rachel</ForeName>
          <Initials>R</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>McArdle</LastName>
          <ForeName>Rachel</ForeName>
          <Initials>R</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Hauger</LastName>
          <ForeName>Richard</ForeName>
          <Initials>R</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Servatius</LastName>
          <ForeName>Richard</ForeName>
          <Initials>R</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Smith</LastName>
          <ForeName>River</ForeName>
          <Initials>R</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Striker</LastName>
          <ForeName>Robert</ForeName>
          <Initials>R</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Mathew</LastName>
          <ForeName>Roy</ForeName>
          <Initials>R</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Gappy</LastName>
          <ForeName>Saib</ForeName>
          <Initials>S</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Pyarajan</LastName>
          <ForeName>Saiju</ForeName>
          <Initials>S</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Gutierrez</LastName>
          <ForeName>Salvador</ForeName>
          <Initials>S</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Gupta</LastName>
          <ForeName>Samir</ForeName>
          <Initials>S</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Aguayo</LastName>
          <ForeName>Samuel</ForeName>
          <Initials>S</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Sharma</LastName>
          <ForeName>Satish</ForeName>
          <Initials>S</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Damrauer</LastName>
          <ForeName>Scott</ForeName>
          <Initials>S</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Kinlay</LastName>
          <ForeName>Scott</ForeName>
          <Initials>S</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Yeh</LastName>
          <ForeName>Shing</ForeName>
          <Initials>S</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Luoh</LastName>
          <ForeName>Shiuh-Wen</ForeName>
          <Initials>SW</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Tuteja</LastName>
          <ForeName>Sony</ForeName>
          <Initials>S</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Mastorides</LastName>
          <ForeName>Stephen</ForeName>
          <Initials>S</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Iyengar</LastName>
          <ForeName>Sudha</ForeName>
          <Initials>S</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Bhushan</LastName>
          <ForeName>Sujata</ForeName>
          <Initials>S</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Muralidhar</LastName>
          <ForeName>Sumitra</ForeName>
          <Initials>S</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Ahuja</LastName>
          <ForeName>Sunil</ForeName>
          <Initials>S</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Liangpunsakul</LastName>
          <ForeName>Suthat</ForeName>
          <Initials>S</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Assimes</LastName>
          <ForeName>Themistocles</ForeName>
          <Initials>T</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Morgan</LastName>
          <ForeName>Timothy</ForeName>
          <Initials>T</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Stapley</LastName>
          <ForeName>Todd</ForeName>
          <Initials>T</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Sun</LastName>
          <ForeName>Yan</ForeName>
          <Initials>Y</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Ballas</LastName>
          <ForeName>Zuhair</ForeName>
          <Initials>Z</Initials>
        </Investigator>
      </InvestigatorList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pmc-release">
          <Year>2023</Year>
          <Month>1</Month>
          <Day>28</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>29</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>7</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>28</Day>
          <Hour>12</Hour>
          <Minute>12</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35089317</ArticleId>
        <ArticleId IdType="pmc">PMC8980930</ArticleId>
        <ArticleId IdType="doi">10.1001/jamainternmed.2021.8538</ArticleId>
        <ArticleId IdType="pii">2788707</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Bowe B, Cai M, Xie Y, Gibson AK, Maddukuri G, Al-Aly Z. Acute kidney injury in a national cohort of hospitalized US veterans with COVID-19. Clin J Am Soc Nephrol. 2020;16(1):14-25. doi:10.2215/CJN.09610620
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2215/CJN.09610620</ArticleId>
            <ArticleId IdType="pmc">PMC7792643</ArticleId>
            <ArticleId IdType="pubmed">33199414</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>May RM, Cassol C, Hannoudi A, et al. . A multi-center retrospective cohort study defines the spectrum of kidney pathology in Coronavirus 2019 disease (COVID-19). Kidney Int. 2021;100(6):1303-1315. doi:10.1016/j.kint.2021.07.015
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.kint.2021.07.015</ArticleId>
            <ArticleId IdType="pmc">PMC8328528</ArticleId>
            <ArticleId IdType="pubmed">34352311</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu J, Ma Z, Raman A, et al. . APOL1 risk variants in individuals of African genetic ancestry drive endothelial cell defects that exacerbate sepsis. Immunity. 2021;54(11):2632-2649.e6. doi:10.1016/j.immuni.2021.10.004
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.immuni.2021.10.004</ArticleId>
            <ArticleId IdType="pubmed">34715018</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bick AG, Akwo E, Robinson-Cohen C, et al. ; VA Million Veteran Program . Association of APOL1 risk alleles with cardiovascular disease in blacks in the Million Veteran Program. Circulation. 2019;140(12):1031-1040. doi:10.1161/CIRCULATIONAHA.118.036589
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1161/CIRCULATIONAHA.118.036589</ArticleId>
            <ArticleId IdType="pmc">PMC6754626</ArticleId>
            <ArticleId IdType="pubmed">31337231</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Grams ME, Rebholz CM, Chen Y, et al. . Race, APOL1 risk, and eGFR decline in the general population. J Am Soc Nephrol. 2016;27(9):2842-2850. doi:10.1681/ASN.2015070763
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1681/ASN.2015070763</ArticleId>
            <ArticleId IdType="pmc">PMC5004654</ArticleId>
            <ArticleId IdType="pubmed">26966015</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Friedman DJ, Kozlitina J, Genovese G, Jog P, Pollak MR. Population-based risk assessment of APOL1 on renal disease. J Am Soc Nephrol. 2011;22(11):2098-2105. doi:10.1681/ASN.2011050519
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1681/ASN.2011050519</ArticleId>
            <ArticleId IdType="pmc">PMC3231785</ArticleId>
            <ArticleId IdType="pubmed">21997396</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen TK, Katz R, Estrella MM, et al. . Association between APOL1 genotypes and risk of cardiovascular disease in MESA (multi-ethnic study of atherosclerosis). J Am Heart Assoc. 2017;6(12):6. doi:10.1161/JAHA.117.007199
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1161/JAHA.117.007199</ArticleId>
            <ArticleId IdType="pmc">PMC5779033</ArticleId>
            <ArticleId IdType="pubmed">29269352</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wasser WG, Tzur S, Wolday D, et al. . Population genetics of chronic kidney disease: the evolving story of APOL1. J Nephrol. 2012;25(5):603-618. doi:10.5301/jn.5000179
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.5301/jn.5000179</ArticleId>
            <ArticleId IdType="pubmed">22878977</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Genovese G, Friedman DJ, Ross MD, et al. . Association of trypanolytic ApoL1 variants with kidney disease in African Americans. Science. 2010;329(5993):841-845. doi:10.1126/science.1193032
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.1193032</ArticleId>
            <ArticleId IdType="pmc">PMC2980843</ArticleId>
            <ArticleId IdType="pubmed">20647424</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>O’Toole JF, Bruggeman LA, Madhavan S, Sedor JR. The cell biology of APOL1. Semin Nephrol. 2017;37(6):538-545. doi:10.1016/j.semnephrol.2017.07.007
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.semnephrol.2017.07.007</ArticleId>
            <ArticleId IdType="pmc">PMC5678957</ArticleId>
            <ArticleId IdType="pubmed">29110761</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tzur S, Rosset S, Shemer R, et al. . Missense mutations in the APOL1 gene are highly associated with end stage kidney disease risk previously attributed to the MYH9 gene. Hum Genet. 2010;128(3):345-350. doi:10.1007/s00439-010-0861-0
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00439-010-0861-0</ArticleId>
            <ArticleId IdType="pmc">PMC2921485</ArticleId>
            <ArticleId IdType="pubmed">20635188</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lipkowitz MS, Freedman BI, Langefeld CD, et al. ; SK Investigators . Apolipoprotein L1 gene variants associate with hypertension-attributed nephropathy and the rate of kidney function decline in African Americans. Kidney Int. 2013;83(1):114-120. doi:10.1038/ki.2012.263
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ki.2012.263</ArticleId>
            <ArticleId IdType="pmc">PMC3484228</ArticleId>
            <ArticleId IdType="pubmed">22832513</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kopp JB, Nelson GW, Sampath K, et al. . APOL1 genetic variants in focal segmental glomerulosclerosis and HIV-associated nephropathy. J Am Soc Nephrol. 2011;22(11):2129-2137. doi:10.1681/ASN.2011040388
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1681/ASN.2011040388</ArticleId>
            <ArticleId IdType="pmc">PMC3231787</ArticleId>
            <ArticleId IdType="pubmed">21997394</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Freedman BI, Kopp JB, Langefeld CD, et al. . The apolipoprotein L1 (APOL1) gene and nondiabetic nephropathy in African Americans. J Am Soc Nephrol. 2010;21(9):1422-1426. doi:10.1681/ASN.2010070730
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1681/ASN.2010070730</ArticleId>
            <ArticleId IdType="pmc">PMC7391383</ArticleId>
            <ArticleId IdType="pubmed">20688934</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Parsa A, Kao WH, Xie D, et al. ; AASK Study Investigators; CRIC Study Investigators . APOL1 risk variants, race, and progression of chronic kidney disease. N Engl J Med. 2013;369(23):2183-2196. doi:10.1056/NEJMoa1310345
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1310345</ArticleId>
            <ArticleId IdType="pmc">PMC3969022</ArticleId>
            <ArticleId IdType="pubmed">24206458</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Freedman BI, Kopp JB, Sampson MG, Susztak K. APOL1 at 10 years: progress and next steps. Kidney Int. 2021;99(6):1296-1302. doi:10.1016/j.kint.2021.03.013
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.kint.2021.03.013</ArticleId>
            <ArticleId IdType="pmc">PMC8154717</ArticleId>
            <ArticleId IdType="pubmed">33794228</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhao B, Lu Q, Cheng Y, et al. ; TRIBE-AKI Consortium . A genome-wide association study to identify single-nucleotide polymorphisms for acute kidney injury. Am J Respir Crit Care Med. 2017;195(4):482-490. doi:10.1164/rccm.201603-0518OC
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1164/rccm.201603-0518OC</ArticleId>
            <ArticleId IdType="pmc">PMC5378420</ArticleId>
            <ArticleId IdType="pubmed">27576016</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Privratsky JR, Li YJ, Haynes C, et al. . Apolipoprotein L1 (APOL1) coding variants are associated with creatinine rise after cardiac surgery. J Cardiothorac Vasc Anesth. 2020;34(12):3314-3320. doi:10.1053/j.jvca.2020.04.017
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1053/j.jvca.2020.04.017</ArticleId>
            <ArticleId IdType="pmc">PMC7655610</ArticleId>
            <ArticleId IdType="pubmed">32434723</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Grams ME, Matsushita K, Sang Y, et al. . Explaining the racial difference in AKI incidence. J Am Soc Nephrol. 2014;25(8):1834-1841. doi:10.1681/ASN.2013080867
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1681/ASN.2013080867</ArticleId>
            <ArticleId IdType="pmc">PMC4116065</ArticleId>
            <ArticleId IdType="pubmed">24722442</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bird L. APOL1 variants contribute to racial disparity in sepsis. Nat Rev Immunol. 2021;21(12):759. doi:10.1038/s41577-021-00647-3
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41577-021-00647-3</ArticleId>
            <ArticleId IdType="pmc">PMC8548855</ArticleId>
            <ArticleId IdType="pubmed">34707254</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nichols B, Jog P, Lee JH, et al. . Innate immunity pathways regulate the nephropathy gene Apolipoprotein L1. Kidney Int. 2015;87(2):332-342. doi:10.1038/ki.2014.270
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ki.2014.270</ArticleId>
            <ArticleId IdType="pmc">PMC4312530</ArticleId>
            <ArticleId IdType="pubmed">25100047</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Magoon S, Bichu P, Malhotra V, et al. . COVID-19-related glomerulopathy: a report of 2 cases of collapsing focal segmental glomerulosclerosis. Kidney Med. 2020;2(4):488-492. doi:10.1016/j.xkme.2020.05.004
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.xkme.2020.05.004</ArticleId>
            <ArticleId IdType="pmc">PMC7275990</ArticleId>
            <ArticleId IdType="pubmed">32775989</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Santoriello D, Khairallah P, Bomback AS, et al. . Postmortem kidney pathology findings in patients with COVID-19. J Am Soc Nephrol. 2020;31(9):2158-2167. doi:10.1681/ASN.2020050744
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1681/ASN.2020050744</ArticleId>
            <ArticleId IdType="pmc">PMC7461662</ArticleId>
            <ArticleId IdType="pubmed">32727719</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kudose S, Batal I, Santoriello D, et al. . Kidney biopsy findings in patients with COVID-19. J Am Soc Nephrol. 2020;31(9):1959-1968. doi:10.1681/ASN.2020060802
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1681/ASN.2020060802</ArticleId>
            <ArticleId IdType="pmc">PMC7461665</ArticleId>
            <ArticleId IdType="pubmed">32680910</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Velez JCQ, Caza T, Larsen CP. COVAN is the new HIVAN: the re-emergence of collapsing glomerulopathy with COVID-19. Nat Rev Nephrol. 2020;16(10):565-567. doi:10.1038/s41581-020-0332-3
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41581-020-0332-3</ArticleId>
            <ArticleId IdType="pmc">PMC7400750</ArticleId>
            <ArticleId IdType="pubmed">32753739</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chaudhary NS, Moore JX, Zakai NA, et al. . APOL1 nephropathy risk alleles and risk of sepsis in blacks. Clin J Am Soc Nephrol. 2019;14(12):1733-1740. doi:10.2215/CJN.04490419
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2215/CJN.04490419</ArticleId>
            <ArticleId IdType="pmc">PMC6895473</ArticleId>
            <ArticleId IdType="pubmed">31704668</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kruzel-Davila E, Wasser WG, Aviram S, Skorecki K. APOL1 nephropathy: from gene to mechanisms of kidney injury. Nephrol Dial Transplant. 2016;31(3):349-358. doi:10.1093/ndt/gfu391
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/ndt/gfu391</ArticleId>
            <ArticleId IdType="pubmed">25561578</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gaziano JM, Concato J, Brophy M, et al. . Million Veteran Program: a mega-biobank to study genetic influences on health and disease. J Clin Epidemiol. 2016;70:214-223. doi:10.1016/j.jclinepi.2015.09.016
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jclinepi.2015.09.016</ArticleId>
            <ArticleId IdType="pubmed">26441289</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Friedman DJ, Pollak MR. APOL1 nephropathy: from genetics to clinical applications. Clin J Am Soc Nephrol. 2021;16(2):294-303. doi:10.2215/CJN.15161219
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2215/CJN.15161219</ArticleId>
            <ArticleId IdType="pmc">PMC7863644</ArticleId>
            <ArticleId IdType="pubmed">32616495</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Friedman DJ, Pollak MR. Genetics of kidney failure and the evolving story of APOL1. J Clin Invest. 2011;121(9):3367-3374. doi:10.1172/JCI46263
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1172/JCI46263</ArticleId>
            <ArticleId IdType="pmc">PMC3163957</ArticleId>
            <ArticleId IdType="pubmed">21881214</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fihn SD, Francis J, Clancy C, et al. . Insights from advanced analytics at the Veterans Health Administration. Health Aff (Millwood). 2014;33(7):1203-1211. doi:10.1377/hlthaff.2014.0054
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1377/hlthaff.2014.0054</ArticleId>
            <ArticleId IdType="pubmed">25006147</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>COVID-19: Shared Data Resource, 2020. Accessed October 15, 2021. https://vhacdwdwhweb100.vha.med.va.gov/phenotype/index.php/COVID-19:Shared_Data_Resource</Citation>
        </Reference>
        <Reference>
          <Citation>Lynch KE, Deppen SA, DuVall SL, et al. . Incrementally transforming electronic medical records into the observational medical outcomes partnership common data model: a multidimensional quality assurance approach. Appl Clin Inform. 2019;10(5):794-803. doi:10.1055/s-0039-1697598
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1055/s-0039-1697598</ArticleId>
            <ArticleId IdType="pmc">PMC6811349</ArticleId>
            <ArticleId IdType="pubmed">31645076</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP; STROBE Initiative . Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ. 2007;335(7624):806-808. doi:10.1136/bmj.39335.541782.AD
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/bmj.39335.541782.AD</ArticleId>
            <ArticleId IdType="pmc">PMC2034723</ArticleId>
            <ArticleId IdType="pubmed">17947786</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Siew ED, Ikizler TA, Matheny ME, et al. . Estimating baseline kidney function in hospitalized patients with impaired kidney function. Clin J Am Soc Nephrol. 2012;7(5):712-719. doi:10.2215/CJN.10821011
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2215/CJN.10821011</ArticleId>
            <ArticleId IdType="pmc">PMC3338282</ArticleId>
            <ArticleId IdType="pubmed">22422536</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Levey AS, Eckardt KU, Dorman NM, et al. . Nomenclature for kidney function and disease: report of a Kidney Disease: Improving Global Outcomes (KDIGO) Consensus Conference. Kidney Int. 2020;97(6):1117-1129. doi:10.1016/j.kint.2020.02.010
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.kint.2020.02.010</ArticleId>
            <ArticleId IdType="pubmed">32409237</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Waikar SS, Wald R, Chertow GM, et al. . Validity of International Classification of Diseases, Ninth Revision, Clinical modification codes for acute renal failure. J Am Soc Nephrol. 2006;17(6):1688-1694. doi:10.1681/ASN.2006010073
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1681/ASN.2006010073</ArticleId>
            <ArticleId IdType="pubmed">16641149</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sohn MW, Arnold N, Maynard C, Hynes DM. Accuracy and completeness of mortality data in the Department of Veterans Affairs. Popul Health Metr. 2006;4:2. doi:10.1186/1478-7954-4-2
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1478-7954-4-2</ArticleId>
            <ArticleId IdType="pmc">PMC1458356</ArticleId>
            <ArticleId IdType="pubmed">16606453</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>King JT Jr, Yoon JS, Rentsch CT, et al. . Development and validation of a 30-day mortality index based on pre-existing medical administrative data from 13,323 COVID-19 patients: The Veterans Health Administration COVID-19 (VACO) Index. PLoS One. 2020;15(11):e0241825. doi:10.1371/journal.pone.0241825
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0241825</ArticleId>
            <ArticleId IdType="pmc">PMC7657526</ArticleId>
            <ArticleId IdType="pubmed">33175863</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gue YX, Tennyson M, Gao J, Ren S, Kanji R, Gorog DA. Development of a novel risk score to predict mortality in patients admitted to hospital with COVID-19. Sci Rep. 2020;10(1):21379. doi:10.1038/s41598-020-78505-w
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41598-020-78505-w</ArticleId>
            <ArticleId IdType="pmc">PMC7721695</ArticleId>
            <ArticleId IdType="pubmed">33288840</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Argenziano MG, Bruce SL, Slater CL, et al. . Characterization and clinical course of 1000 patients with coronavirus disease 2019 in New York: retrospective case series. BMJ. 2020;369:m1996. doi:10.1136/bmj.m1996
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/bmj.m1996</ArticleId>
            <ArticleId IdType="pmc">PMC7256651</ArticleId>
            <ArticleId IdType="pubmed">32471884</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hemmelgarn BR, Manns BJ, Lloyd A, et al. ; Alberta Kidney Disease Network . Relation between kidney function, proteinuria, and adverse outcomes. JAMA. 2010;303(5):423-429. doi:10.1001/jama.2010.39
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jama.2010.39</ArticleId>
            <ArticleId IdType="pubmed">20124537</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hunter-Zinck H, Shi Y, Li M, et al. ; VA Million Veteran Program . Genotyping array design and data quality control in the Million Veteran Program. Am J Hum Genet. 2020;106(4):535-548. doi:10.1016/j.ajhg.2020.03.004
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ajhg.2020.03.004</ArticleId>
            <ArticleId IdType="pmc">PMC7118558</ArticleId>
            <ArticleId IdType="pubmed">32243820</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fang H, Hui Q, Lynch J, et al. ; VA Million Veteran Program . Harmonizing genetic ancestry and self-identified race/ethnicity in genome-wide association studies. Am J Hum Genet. 2019;105(4):763-772. doi:10.1016/j.ajhg.2019.08.012
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ajhg.2019.08.012</ArticleId>
            <ArticleId IdType="pmc">PMC6817526</ArticleId>
            <ArticleId IdType="pubmed">31564439</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Levey AS, Stevens LA, Schmid CH, et al. ; CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) . A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604-612. doi:10.7326/0003-4819-150-9-200905050-00006
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.7326/0003-4819-150-9-200905050-00006</ArticleId>
            <ArticleId IdType="pmc">PMC2763564</ArticleId>
            <ArticleId IdType="pubmed">19414839</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Peterson B, Harrell FE. Partial proportional odds models for ordinal response variables. Applied Stats. 1990;39:205-17. doi:10.2307/2347760</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2307/2347760</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brant R. Assessing proportionality in the proportional odds model for ordinal logistic regression. Biometrics. 1990;46(4):1171-1178. doi:10.2307/2532457
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2307/2532457</ArticleId>
            <ArticleId IdType="pubmed">2085632</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Limou S, Nelson GW, Kopp JB, Winkler CA. APOL1 kidney risk alleles: population genetics and disease associations. Adv Chronic Kidney Dis. 2014;21(5):426-433. doi:10.1053/j.ackd.2014.06.005
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1053/j.ackd.2014.06.005</ArticleId>
            <ArticleId IdType="pmc">PMC4157456</ArticleId>
            <ArticleId IdType="pubmed">25168832</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mukamal KJ, Tremaglio J, Friedman DJ, et al. . APOL1 genotype, kidney and cardiovascular disease, and death in older adults. Arterioscler Thromb Vasc Biol. 2016;36(2):398-403. doi:10.1161/ATVBAHA.115.305970
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1161/ATVBAHA.115.305970</ArticleId>
            <ArticleId IdType="pmc">PMC4732891</ArticleId>
            <ArticleId IdType="pubmed">26634651</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gutiérrez OM, Irvin MR, Zakai NA, et al. . APOL1 nephropathy risk alleles and mortality in African American adults: a cohort study. Am J Kidney Dis. 2020;75(1):54-60. doi:10.1053/j.ajkd.2019.05.027
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1053/j.ajkd.2019.05.027</ArticleId>
            <ArticleId IdType="pmc">PMC7008402</ArticleId>
            <ArticleId IdType="pubmed">31563468</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Beckerman P, Susztak K. APOL1: the balance imposed by infection, selection, and kidney disease. Trends Mol Med. 2018;24(8):682-695. doi:10.1016/j.molmed.2018.05.008
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.molmed.2018.05.008</ArticleId>
            <ArticleId IdType="pmc">PMC6101980</ArticleId>
            <ArticleId IdType="pubmed">29886044</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bruggeman LA, O’Toole JF, Sedor JR. APOL1 polymorphisms and kidney disease: loss-of-function or gain-of-function?
Am J Physiol Renal Physiol. 2019;316(1):F1-F8. doi:10.1152/ajprenal.00426.2018
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1152/ajprenal.00426.2018</ArticleId>
            <ArticleId IdType="pmc">PMC6383195</ArticleId>
            <ArticleId IdType="pubmed">30332315</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McCarthy GM, Blasio A, Donovan OG, et al. . Recessive, gain-of-function toxicity in an APOL1 BAC transgenic mouse model mirrors human APOL1 kidney disease. Dis Model Mech. 2021;14(8):14. doi:10.1242/dmm.048952
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1242/dmm.048952</ArticleId>
            <ArticleId IdType="pmc">PMC8353097</ArticleId>
            <ArticleId IdType="pubmed">34350953</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lan X, Jhaveri A, Cheng K, et al. . APOL1 risk variants enhance podocyte necrosis through compromising lysosomal membrane permeability. Am J Physiol Renal Physiol. 2014;307(3):F326-F336. doi:10.1152/ajprenal.00647.2013
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1152/ajprenal.00647.2013</ArticleId>
            <ArticleId IdType="pmc">PMC4121568</ArticleId>
            <ArticleId IdType="pubmed">24899058</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Beckerman P, Bi-Karchin J, Park AS, et al. . Transgenic expression of human APOL1 risk variants in podocytes induces kidney disease in mice. Nat Med. 2017;23(4):429-438. doi:10.1038/nm.4287
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nm.4287</ArticleId>
            <ArticleId IdType="pmc">PMC5603285</ArticleId>
            <ArticleId IdType="pubmed">28218918</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Granado D, Müller D, Krausel V, et al. . Intracellular APOL1 risk variants cause cytotoxicity accompanied by energy depletion. J Am Soc Nephrol. 2017;28(11):3227-3238. doi:10.1681/ASN.2016111220
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1681/ASN.2016111220</ArticleId>
            <ArticleId IdType="pmc">PMC5661279</ArticleId>
            <ArticleId IdType="pubmed">28696248</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Olabisi OA, Zhang JY, VerPlank L, et al. . APOL1 kidney disease risk variants cause cytotoxicity by depleting cellular potassium and inducing stress-activated protein kinases. Proc Natl Acad Sci USA. 2016;113(4):830-837. doi:10.1073/pnas.1522913113
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.1522913113</ArticleId>
            <ArticleId IdType="pmc">PMC4743809</ArticleId>
            <ArticleId IdType="pubmed">26699492</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
